![]() | |
Clinical data | |
---|---|
Trade names | Pelubi |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H18O3 |
Molar mass | 258.317 g·mol−1 |
3D model (JSmol) | |
| |
|
Pelubiprofen is a nonsteroidal anti-inflammatory drug of the profen class used to treat back pain and osteoarthritis.[1]
Pelubiprofen was developed in South Korea by Daewon Pharmaceuticals and it is marketed in Korea and Russia,[2] among other countries.
Pelubiprofen is being studied for use in combination with eperisone.[3]
Because pelubiprofen has low water solubility, development of salt formulations with better solubility are being studied.[4]
1-(1-piperidino)cyclohexene [2981-10-4] (1) ethyl 2-(4-formylphenyl)propanoate [43153-04-4] (2) ethyl 2-(4-(2-oxo-1-cyclohexylidenemethyl)phenyl)propionate, PC54259840 (3)
| |
---|---|
pyrazolones / pyrazolidines |
|
salicylates |
|
acetic acid derivatives and related substances |
|
oxicams |
|
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) |
|
COX-2 inhibitors (coxibs) |
|
other |
|
NSAID combinations |
|
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
|
![]() | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |